Alpha Metallurgical Resources

CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR). TRANSCEND is designed to enroll approximately 120 kidney transplant recipients with late AMR.» Mehr auf globenewswire.com

Alpha Metallurgical Resources benefits from strong demand for met coal in developing markets like India, which supports long-term revenue growth despite global renewable energy trends. AMR's higher average selling prices and significant share buybacks position it as a more attractive investment compared to peers like BTU and HCC. Despite short-term price fluctuations and long-term renewable energy risks, AMR's robust financials and market position offer a 38.8% upside potential.» Mehr auf seekingalpha.com

Alpha Metallurgical Resources, Inc. is the largest U.S. metallurgical coal miner, facing weak coking coal prices but still generating positive free cash flow. Q4 2024 results showed an $8M EBITDA increase and a minor $2M net loss, with stable sales volumes and slight price declines. AMR is well-capitalized, with $482M in cash and $519M in liquidity.» Mehr auf seekingalpha.com